Cerevel Therapeutics Holdings, Inc. (CERE) [Rocket]

In millions, except per share items	Dec-31-22	Dec-31-21	Dec-05-21	Dec-31-20	Dec-05-20	Dec-31-19
	10-K	10-K	8-K	10-K	8-K	10-K
Revenues	0.0	0.0	161.9	0.0	103.3	0.0
Revenue growth			56.7%
Cost of goods sold	0.0	0.0	323.7	0.0	206.6	0.0
Gross profit	0.0	0.0	-161.9	0.0	-103.3	0.0
Gross margin			-100.0%		-100.0%
Selling, general and administrative [+]		220.1	58.2	149.1	45.8	83.5
General and administrative	0.0		58.2		45.8
Other operating expenses		1.4		-149.1		-83.5
EBITDA [+]		-218.7		0.4		0.2
EBITDA growth	-100.0%	-55193.7%	47.6%	124.3%
EBITDA margin			-136.0%		-144.3%
Depreciation and amortization		2.7		0.4		0.2
EBIT [+]	0.0	-221.5	-220.1	0.0	-149.1	0.0
EBIT growth	-100.0%		47.6%
EBIT margin			-136.0%		-144.3%
Interest expense, net [+]			-0.2		-0.2
Interest expense	3.9
Interest income			0.2		0.2
Other income (expense), net [+]	3.9	-3.9	-5.4	-152.2	-3.3	-128.3
Other	-0.3
Pre-tax income	0.0	-225.3	-225.3	-152.2	-152.2	-128.3
Income taxes	0.0	0.0	0.0	0.0	0.0	0.0
Tax rate		0.0%	0.0%	0.0%	0.0%
Net income	0.0	-225.3	-225.3	-152.1	-152.1	-128.4
Net margin			-139.2%		-147.3%

Basic EPS [+]		($1.65)	($225,334.00)	($2.07)	($148,271.00)	($2.90)
Growth		-20.1%	52.0%	-28.9%
Diluted EPS [+]		($1.65)	($1.56)	($2.07)	($2.42)	($2.90)
Growth		-20.1%	-35.4%	-28.9%

Shares outstanding (basic) [+]		136.6	0.0	73.6	0.0	44.2
Growth		85.5%	-2.5%	66.6%
Shares outstanding (diluted) [+]		136.6	144.3	73.6	63.0	44.2
Growth		85.5%	129.2%	66.6%

EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges.